Reference No: Author(s) Approval date: June Committee. Operational Date: July Review:
|
|
- Ira Davidson
- 6 years ago
- Views:
Transcription
1 Reference No: Title: Author(s) Systemic anti-cancer therapy (SACT) guidelines for renal cell cancer Dr Alison Clayton Consultant Medical Oncologist & Dr Jane Hurwitz Consultant Medical Oncologist, Cancer Centre, Belfast City Hospital Ownership: Approval by: Operational Date: NICaN NICaN Drugs & Therapeutics Committee July 2016 Version No. 2.0 Supercedes 1.0 Links to other policies Version control for drafts: NICaN Renal SACT protocols Approval date: Next Review: June 2016 July 2018 Date Version Author Comments 2012 V1.0 A Clayton June 2016 V2.0 A Clayton Nivolumab included Other supportive therapies Denosumab added SACT for Renal Cell Cancer 2016 v2.0 Page 1 of 20
2 Authorisation of Systemic Anti-Cancer Therapy (SACT) Guidelines for Renal Cell Cancer These SACT guidelines are being submitted by the authors on behalf of the renal oncologists. SACT for Renal Cell Cancer 2016 v2.0 Page 2 of 20
3 1.0 INTRODUCTION / PURPOSE OF POLICY 1.1 Background These guidelines describe the agreed management for patients with renal cell cancer. They include staging and prognostic scores, the role of surgery and systemic anti-cancer therapy (SACT). 1.2 Purpose To ensure management for patients with renal cell cancer. 2.0 SCOPE OF THE POLICY This document is aimed at all clinical staff involved in the management of patients with renal cell cancer. 3.0 ROLES/RESPONSIBILITIES It is the responsibility of all clinical staff involved in the management of patients with renal cell cancer to familiarise themselves with these guidelines. 4.0 KEY POLICY PRINCIPLES 4.1 Histological sub-types and staging conventional = clear cell papillary chromophobe collecting duct medullary unclassified Sarcomatoid change may be seen with all types SACT for Renal Cell Cancer 2016 v2.0 Page 3 of 20
4 TNM STAGING T1 T2 T3 T1a < 4cm T1b > 4cm < 7 cm limited to the kidney > 7 cm limited to the kidney T2a < 10 cm T2b > 10cm Tumor extends into major veins or invades adrenal gland or perinephric tissues but not beyond Gerota fascia T3a Invades adrenal gland or peri-nephric tissues but not beyond Gerota fascia T3b Extends into renal vein or its segmental (muscle- containing) branches, or vena cava below the diaphragm T3c Extends into IVC above diaphragm or invades the wall of the vena cava T4 N0 N1 N2 M0 M1 Invades beyond Gerota fascia No nodes Single regional node (renal hilar, paraaortic, paracaval) >1 regional node No distant metastases Distant metastases SACT for Renal Cell Cancer 2016 v2.0 Page 4 of 20
5 STAGE GROUPING (1997) STAGE 5yr OS (%) GUINAN 1995 TSUI 2000 I T1, NO, MO II T2, NO, MO III T1-2, N1, MO T3, NO-1, MO IV T1-4, N2, MO T4, NO-2, M0-1 T1-4, N0-1, M1 (N=2473) (N=643) AJCC STAGE 2010 (7TH ED) STAGE I II III IV TNM T1, NO, MO T2, NO, MO T1-2, N1, MO T3, NO-1, MO T4, Any N, M0 Any T, Any N, M1 4.2 Management of localised disease Treatment options for localised disease include radical nephrectomy with or without lymph node dissection, partial nephrectomy, and non- surgical techniques (such as radiofrequency ablation) for selected patients with small, generally T1a tumours. Surgery is indicated for patients with clinical stage III disease (i.e. patients who have a tumour involving the renal vein or vena cava). Patients with minimal regional adenopathy may also be considered for SACT for Renal Cell Cancer 2016 v2.0 Page 5 of 20
6 surgery, as lymph nodes suspicious for disease on CT may be hyperplastic and may not be involved with the tumour Prognosis following nephrectomy UCLA Integrated Staging System (UISS) 1 UISS 1997 Grade ECOG 2yr survival 5yr survival TNM stage I I 1,2 0 96% 94% II I 1,2 >1 89% 67% I 3,4 Any II Any Any III Any 0 III 1 >1 III III 2-4 >1 66% 39% IV 1,2 0 IV IV 3,4 0 42% 23% 1-3 >1 V IV 4 >1 9% 0% SACT for Renal Cell Cancer 2016 v2.0 Page 6 of 20
7 Liebovich score 2 Feature Pathological T category of primary tumour (TNM 2002) Score pt1a 0 pt1b 2 pt2 3 pt3a-4 4 Regional lymph node status pnx or pn0 0 pn1 or pn2 2 Tumour size < 10cm 0 > 10cm 1 Nuclear grade 1 or Histological tumour necrosis No 0 Yes 1 Score Group 0 2 Low risk 3 5 Intermediate risk 6 or more High risk SACT for Renal Cell Cancer 2016 v2.0 Page 7 of 20
8 4.2.2 Adjuvant therapy There is currently no convincing data to support the use of either adjuvant radiotherapy or adjuvant systemic therapy as standard practice. Adjuvant therapy should only be given as part of a clinical trial. 4.3 Metastatic renal cancer Prognostic scores MSK score The prognostic scores developed at the Memorial Sloane Kettering hospital are widely used as reported by Motzer (developed when immunotherapy was the mainstay of treatment) based on 670 patients with advanced RCC 3 Score (1 for each): No nephrectomy KPS < 80 Hb < LLN Ca > 2.5 LDH > 1.5 X ULN SACT for Renal Cell Cancer 2016 v2.0 Page 8 of 20
9 Score 0 1 or Median survival (mnths) follow-up analysis, based on 463 patients with advanced RCC who have undergone nephrectomy 4 Score (1 for each): Time from diagnosis to interferon < 1yr KPS < 80 Hb < LLN Ca > 2.5 LDH > 1.5 X ULN Score 0 1 or Median survival (mnths) HENG score 5 - based on analysis of outcomes of 645 patients treated with anti-vegf therapy. Score (1 for each): Time from diagnosis to treatment < 1yr KPS < 80 HB < LLN CA > 2.5 Neutrophils > ULN Plt> ULN Score 0 1 or Median survival (mnths) NR year OS (%) SACT for Renal Cell Cancer 2016 v2.0 Page 9 of 20
10 4.3.2 Role of surgery Nephrectomy Nephrectomy should be considered for all patients with metastatic renal cell cancer (RCC) with a good performance status (ECOG PS < 1). Two randomised controlled trials have demonstrated a survival benefit for patients with metastatic RCC undergoing nephrectomy followed by interferon compared with interferon alone, with a median overall survival of 11.1 vs 8.1 months (p= 0.05) 6 and 17 vs 7 months (p= 0.03) 7. A combined analysis of these studies showed a median overall survival of 13.6 vs. 7.8 months 8. The role of nephrectomy for patients receiving anti-vegf / TKI therapy is being re-appraised in two randomised phase III trials (CARMENA / EORTC). Retrospective data in patients treated with anti-vegf/tki therapy still suggests patients benefit from nephrectomy and this should therefore still be considered pending results of phase III studies Metastasectomy Selected patients with stage IV RCC with a solitary metastasis should be considered for resection of the metastasis 9. Data suggest this is more likely to be of benefit in patients with metachronous rather than synchronous metastases, particularly if there is a disease free interval of > 12 months. Sites of solitary metastases that are amenable to this approach include the lung, bone, brain, and other selected sites. Both the primary tumour and the metastasis may be resected during the same operation or at different times. Although the majority of patients who undergo resection of a solitary will relapse, long- term survival has been observed in some patients. Radiotherapy should be considered following resection of bone or brain metastases Renal embolisation Renal embolisation may be considered for patients with metastatic RCC who are not suitable for nephrectomy and who are symptomatic from their primary tumour 10, 11. SACT for Renal Cell Cancer 2016 v2.0 Page 10 of 20
11 4.3.3 Systemic therapy First line therapy Background Sunitinib or Pazopanib are currently standard first line therapy options for metastatic renal cell carcinoma with good performance status (ECOG 0-1). The benefits of sunitinib were demonstrated a large phase III trial in patients with clear cell histology, predominantly post-nephrectomy. Patients with nonclear cell histology may also receive a trial of sunitinib therapy (as per NICE guidance). There are no dedicated trials to guide therapy in this smaller group. However, there is some evidence of activity of sunitinib in patients with non-clear cell histology from the expanded access study and reports in small numbers of patients. Benefits in this group are however less certain in view of the lower quality of evidence. Interferon may be considered for patients with PS 2, or for patients with a contra-indication or intolerance to sunitinib and pazopanib. Patients who have small volume asymptomatic disease may be monitored initially prior to commencing systemic therapy as some patients may have very indolent disease which may remain relatively stable without intervention sometimes for long periods of time. Baseline investigations All patients; Biopsy (mandatory to establish histological diagnosis in patients not undergoing cytoreductive nephrectomy) FBC Oncology profile CT thorax, abdomen and pelvis Isotope bone scan Patients being considered for sunitinib therapy; ECG Echocardiogram Thyroid function Dental review SACT for Renal Cell Cancer 2016 v2.0 Page 11 of 20
12 Monitoring response to therapy Patients receiving systemic therapy for metastatic disease should have restaging investigations repeated every 3-4 months on therapy to assess response Anti-VEGFR TKI therapy Sunitinib Sunitinib maleate is an oral multi-targeted receptor tyrosine kinase inhibitor which has demonstrated both anti-tumour and anti-angiogenic effects. Sunitinib maleate selectively inhibits PDGFR, VEGFR 1-3, c-kit and FLT-3- receptors. Sunitinib is licenced as first line therapy for locally advanced or metastatic renal cell carcinoma. In the pivotal phase III trial, 750 patients with metastatic renal cell carcinoma (clear cell type) who had not received prior systemic therapy for MRCC and were of good performance status (PS 0-1) were randomised to receive sunitinib or IFN-α 12. Sunitinib treatment was associated with a clinically and statistically significant improvement in median PFS compared to IFN- (11 vs 5 months; hazard ratio [HR] =0.415; p ) and overall survival (overall analysis vs 21.8 months, p=0.051 ; crossover patients censored 26.4 vs 20 months, p=0.036 ; patients not receiving second line therapy 28.1 vs 14.1 months, p=0.0033). The ORR was 37 vs 9%. Regimen 50mg OD PO days 1-28, followed by 14 days without treatment (6 week cycle). For dose modifications, see individual protocol. Pazopanib Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor of VEGFR 1-3, PDGFR-α and β, and stem cell factor receptor (c- KIT). In a phase III RCT 435 patients with locally advanced or metastatic RCC (treatment naive and cytokine pre-treated) received pazopanib or placebo 13. This demonstrated improved PFS (9.2 vs 4.2 months, HR 0.46, p < ) response rate (30 vs 3%, p < 0.001) for pazopanib. SACT for Renal Cell Cancer 2016 v2.0 Page 12 of 20
13 Pazopanib has been compared to sunitinib in 1110 patients with locally advanced and/or metastatic RCC who had not received prior systemic therapy 14. There was no significant difference in PFS (8.4 vs 9.5 months) or OS (28.4 vs 29.3 months) in the two groups. The trial achieved its primary endpoint of non-inferiority in PFS compared to sunitinib. The QOL/toxicity data favoured pazopnib, however assessments were performed at the end of the 4th week on sunitinib when toxicity on that arm would be maximal, and response assessments were performed at the end of the sixth week and so trial design was not optimal. Incidence of hand/foot syndrome, rash, peripheral oedema, stomatitis, fatigue and myelosuppression were lower in the pazopanib arm, but incidence of liver toxicity, alopecia and weight loss was higher. Regimen 800mg OD PO continuously. For dose modifications, see individual protocol m-tor inhibitors Temsirolimus Temsirolimus is not funded Northern Ireland Temsirolimus acts by inhibiting the mammalian target of rapamycin (mtor) kinase. Temsirolimus is licenced for the first line treatment of patients with RCC who have at least three of six prognostic factors denoting poor risk as indicated below; 1. LDH > 1.5 x upper limit of normal 2. Haemoglobin < lower limit of normal 3. Corrected calcium > 10mg/dL (> 2.5mM) 4. Time from diagnosis to first treatment 1 year 5. Karnofsky Performance Status Multiple (2 or more) sites of metastasis In the pivotal phase III study, 626 patients with advanced RCC and at least 3 of the above prognostic factors, were randomised to INF-α only, temsirolimus only, or temsirolimus plus IFN-α.Temsirolimus as a single agent significantly improved OS and PFS compared to IFN-α alone (10.9 vs. 7.3 months; p=0.008 and 3.8 vs. 1.9 months; p<0.00). This was not improved with the combination of temsirolimus and IFN 15. SACT for Renal Cell Cancer 2016 v2.0 Page 13 of 20
14 Choice of initial therapy The majority of patients commence sunitinib therapy; unless there are particular aspects of side effect profile which favour the use of pazopanib in particular patients. Patients responding to sunitinib who experience toxicity problems which are likely to be less with pazopanib should be considered for a change of treatment to pazopanib. Patients with small volume, asymptomatic indolent disease may have a period of active surveillance without treatment for a time prior to commencing active therapy as there is no evidence that this has an adverse impact on prognosis Immunotherapy High dose IL-2 Selected patients may be considered for supra-regional referral to the Christie hospital for assessment for suitability for high dose interleukin-2 treatment Interferon- α. IFN α may be considered for patients with PS 2, or for patients with a contraindication or intolerance to anti-vegfr TKI agents. In the MRC RE-01 trial patients were randomised to IFN α or megace. There was an improved ORR (14 vs 2%), I year survival (43 vs 31%) and OS (8.5 vs 6 months) for IFN α compared to megace. Other studies have shown similar results, with response rates of % and median OS of 8-13 months There is no convincing evidence that combination immuno/chemotherapy is superior to interferon alone One RCT demonstrated a survival advantage for the use of the atzpodien regimen over interferon and vinblastine, but this was not confirmed in the MRC RE-04 study. Regimen IFN α 5 MU subcutaneous 3 X weekly for 1 week then increasing to 10 MU 3 X weekly. For less fit patients consider starting dose of 3MU, increasing to 5 MU if tolerated. SACT for Renal Cell Cancer 2016 v2.0 Page 14 of 20
15 Second line therapy Following prior cytokine therapy Sunitinib Results are available from two independent, single arm, multicentre, phase II trials of sunitinib 24, 25. The trials include a total of 168 patients receiving sunitinib for the treatment of metastatic renal cell carcinoma following failure of prior cytokine therapy. ORR was 42%, and 24% achieved SD was > 3 months. Sorafenib 26 and pazopanib 27 are also licensed for this indication however in this centre we would use sunitinib. Following prior anti-vegfr TKI therapy Axitinib Axitinib is currently the standard second line therapy for patients retaining a good performance status (ECOG 0-1) whose disease has progressed on sunitinib in line with NICE guidance (TA333) Axitinib is a potent and selective tyrosine kinase inhibitor of (VEGFR-1, VEGFR-2 and VEGFR-3. It is licenced for the treatment of adult patients with advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine. The AXIS trial was a phase III study in which 723 patients with advanced RCC whose disease had progressed on or after treatment with one prior systemic therapy were randomised to receive axitinib or sorafenib patients (53.8%) had received one prior sunitinib-based therapy and 251 patients (34.7%) had received one prior cytokine-based therapy (IL-2 or INFα). Median PFS and OS were 6.8 vs 4.7 months (p<0.0001) and 20/1 vs 19.2 months (NS), for axitinib and sorafinib respectively. ORR was 19.4 vs 9.4% (p<0.0001). In patients who had received prior sunitinib, the median PFS and OS were 4.8 vs 3.4 months (p<0.0063) and 15.2 vs 16.5 months (NS). Regimen 5mg PO BD continuously with dose adjustment (escalation or reduction) according to toxicity as per SPC SACT for Renal Cell Cancer 2016 v2.0 Page 15 of 20
16 Everolimus Everolimus is not currently funded routinely in Northern Ireland Individual funding requests for second line everolimus may be considered for patients felt unsuitable for treatment with axitinib Everolimus is an oral mtor inhibitor that is licensed for use following failure of an anti-vegf agent. The RECORD 1 phase III trial randomised 410 patients who had received at least one prior anti VEGF therapy, to everolimus or placebo. PFS was improved in the treatment arm (4.9 vs 1.9 monts; p<0.001). Median OS was 14.8 vs 14.4 months (p=0.162), although this may be confounded by cross0over (80% patients crossed over to receive everolimus) 28. Regimen 10mg OD PO continuously Nivolumab Nivolumab is not currently funded routinely in Northern Ireland Individual funding requests for second line nivolumab may be considered for patients felt unsuitable for treatment with axitinib Nivolumab is a PD-1 checkpoint inhibitor, licensed for treatment of metastatic renal carcinoma following failure of TKI therapy. The data to support the benefits of nivolumab comes from the CHECKMATE 2015 study 29. This study included 821 patients with advanced clear cell renal cell carcinoma who had received up to 2 previous regimens of anti angiogenic therapy. The patients were randomised to receive nivolumab or everolimus. There was a significant improvement in median OS for the nivolumab group (25 compared to 19.6 months). The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P = 0.002). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). Regimen 3mg/kg IV over 60 mins 2 weekly Immunotherapy Patients retaining good performance status following progression on first line anti-vegfr TKI therapy may be considered for treatment with INF-α. These patients could also be considered for referral for consideration of high dose IL- 2 or a clinical trial. SACT for Renal Cell Cancer 2016 v2.0 Page 16 of 20
17 4.3.4 Other supportive therapies Bisphosphonates Zolendronic acid 4 mg IV monthly or alternatively oral bondronat may be considered for patients with bone metastases. Denosumab may be considered as an alternative to bisphosphonate for patients with bony metastatic disease 5.0 IMPLEMENTATION OF POLICY 5.1 Dissemination This policy will be agreed by all consultant oncologists treating patients with SACT for breast cancer. The guideline will form the basis for development of the SACT regimen specific protocols. It will be available on the intranet for use by all doctors, nurses and pharmacists involved in all stages of SACT assessment and delivery in patients with breast cancer. 6.0 MONITORING Use of these guidelines will be monitored using audit. SACT for Renal Cell Cancer 2016 v2.0 Page 17 of 20
18 7.0 EVIDENCE BASE / REFERENCES 1. Zisman A, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. Clin Oncol. 2002;20(23): Leibovich BC, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer Dec 15;98(12): Motzer RJ, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol Aug;17(8): Motzer RJ, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol Feb 1;22(3): Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol Dec 1;27(34): doi: /JCO Epub 2009 Oct Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with Interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345: Mickisch GHJ, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: Flanigan RC, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer. A combinedanalysis. J.Urology 2004; 171: Kavolius JP, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: Munro NP, et al. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int Aug;92(3): Kalman D, Varenhorst E. The role of arterial embolization in renal cell carcinoma. Scand J Urol Nephrol Jun;33(3): Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med Jan 11;356(2): Sternberg CN, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma:Results of a Randomized Phase III Trial. J Clin Oncol 28(2010) Motzer RJ, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med Aug 22;369(8): Hudes G, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal- Cell Carcinoma. N Eng J Med 2007;356: SACT for Renal Cell Cancer 2016 v2.0 Page 18 of 20
19 16. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet Jan 2;353(9146): Pyrhonen S, et al. Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer. J Clin Oncol : Motzer RJ, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1): Minasian LM, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993;11(7): Negrier S, et al. Recombinant human interleukin-2, recombinant human interferon alfa- 2a, or both in metastatic renal-cell carcinoma. Groupe Français d'immunothérapie. N Engl J Med. 1998;338(18): Atzpodien J, et al. Interleukin-2 and Interferon Alfa-2a Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of thegerman Cooperative Renal Carcinom Chemoimmunotherapy Group (DGCIN).J Clin Oncol : Gore ME, et al. Interferon-α (IFN), interleukin-2 (IL2) and 5-fluorouracil (5FU) vs IFN alone in patients with metastatic renal cell carcinoma (mrcc): results of the randomised MRC/EORTC RE04 trial. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5039) 23. Negrier S, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol Dec 15;18(24): Motzer R, et al. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol Jan 1;24(1): Motzer RJ, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA Escudier B, et al. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol July 2009 vol. 27 no Sternberg CN, et al. Randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer Apr;49(6): Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637): Motzer et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New Engl J of Medicine 2015, Volume 273 No. 19. SACT for Renal Cell Cancer 2016 v2.0 Page 19 of 20
20 30. Rini B, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet Dec 3;378(9807): CONSULTATION PROCESS Northern Ireland renal oncologists 9.0 EQUALITY STATEMENT In line with duties under the equality legislation (Section 75 of the Northern Ireland Act 1998), Targeting Social Need Initiative, Disability discrimination and the Human Rights Act 1998, an initial screening exercise to ascertain if this policy should be subject to a full impact assessment has been carried out. The outcome of the Equality screening for this policy is: Major impact Minor impact No impact. SACT for Renal Cell Cancer 2016 v2.0 Page 20 of 20
Medical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationGuidelines on Renal Cell
Guidelines on Renal Cell Carcinoma (Text update March 2009) B. Ljungberg (Chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction Renal cell carcinoma
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationReference No: Author(s) NICaN Drugs and Therapeutics Committee. Approval date: 12/05/16. January Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Gastro- Intestinal Stromal Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationGUIDELINES ON RENAL CELL CARCINOMA
GUIDELINES ON RENAL CELL CARCINOMA B. Ljungberg (chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction This EAU guideline was prepared to help urologists
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationComplex case Presentations
Complex case Presentations Case Presentations April 2016 Lisa M Pickering Case presentations: chromophobe renal carcinoma 60 year old man. ECOG PS 0 No significant comorbodities August 2009: L radical
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationAuthor(s) Approval date: 12/05/16. Committee. June Operational Date: Review: Version No. 1.1 Supercedes 1.0 Links to other policies
Reference No: Title: Author(s) Ownership: Approval by: Operational Date: Systemic Anti-Cancer Therapy (SACT) Guidelines for Peritoneal Mesothelioma Professor Richard Wilson (Consultant/Chair in Cancer
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationSustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma
JOURNAL OF CASE REPORTS 2015;5(1):280-284 Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma Chanchal Goswami, Aditi Mandal B. P. Poddar Hospital & Medical Research
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Cabozantinib for untreated locally advanced or metastatic renal cell carcinoma Final scope Remit/appraisal objective To appraise
More informationRenal cell cancer: overview and immunochemotherapy
1 Renal cell cancer: overview and immunochemotherapy Vincent Khoo Introduction and epidemiology Kidney cancer is a relatively common urological cancer, accounting for approximately 2% of all adult cancers.
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationManchester Cancer. Guidelines for the management of renal cancer
Guidelines for the management of renal cancer Approved by the urology pathway board September 2014 To be reviewed September 2016 Renal Cancer Guidelines 1. Introduction 1.1 Kidney cancer accounts for 3%
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationDose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring
Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring Alison Zhang 1, Peter Fox 1, Sally Coulter 4, Val Gebski 5, Bavanthi Balakrishnar 1, Christopher Liddle
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationEAU GUIDELINES ON RENAL CELL CARCINOMA
EAU GUIDELINES ON RENAL ELL ARINOMA (Limited text update March 2016) B. Ljungberg (hair), K. Bensalah, A. Bex (Vice-chair), S. anfield, R.H. Giles (Patient Organisation Representative), M. Hora, M.A. Kuczyk,
More informationGuidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationComplete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy
Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy Is complete remission an achievable goal in mrcc? Lessons from observation Lessons from immunotherapy Current status in
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationAdvanced & Metastatic Renal Cell Carcinoma
Advanced & Metastatic Renal Cell Carcinoma An Update G. Renzulli January 2013 1 Overview of Cancers of the Kidney 2 Global Epidemiology 3 Global Epidemiology of Kidney Cancer 4 Globally, kidney cancer
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationRenal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto)
Renal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Nimira Alimohamed (Staff Medical Oncologist, University of Calgary)
More informationCheckMate 025, as patients may derive a benefit, based on the opinion of the CGP and the mechanism of action of nivolumab.
CheckMate 025, as patients may derive a benefit, based on the opinion of the CGP and the mechanism of action of nivolumab. perc noted that patients with brain metastases were excluded from the CheckMate
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationAxitinib in renal cell carcinoma: now what do we do?
Renal Cell Carcinoma Axitinib in renal cell carcinoma: now what do we do? Ian D. Davis Monash University Eastern Health Clinical School, Level 2, Box Hill, Victoria 3128, Australia Correspondence to: Ian
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Kidney Cancer. Version February 6, NCCN.org.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 3.2018 February 6, 2018 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version 3.2018, 02/06/18
More informationOpinion 26 June 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 26 June 2013 VOTRIENT 200 mg, film-coated tablets B/30 (CIP: 491 313 4) VOTRIENT 400 mg, film-coated tablets B/30
More informationWhat can we expect from running phase III trials: will all of them alter the current treatment algorithm?
What can we expect from running phase III trials: will all of them alter the current treatment algorithm? 8 th European International Kidney Cancer Symposium Budapest, May 2013 Martin Gore PhD FRCP Royal
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationPrognostic Factors for mrcc: Relevance in Clinical Practice
Prognostic Factors for mrcc: Relevance in Clinical Practice Daniel Heng MD MPH FRCPC Chair, GU Tumor Group Tom Baker Cancer Center University of Calgary Prognostic Factors Patient Factors Performance Status
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationLenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]
Contains AIC Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] Multiple Technology Appraisal Background and Clinical Effectiveness Lead team: Femi Oyebode
More informationRENAL CANCER GUIDELINES
Greater Manchester and Cheshire Cancer Network RENAL CANCER GUIDELINES Agreed by Urology CSG: July 2010 Review Date: July 2012 Renal Cancer Guidelines 1. Introduction 1.1 Kidney cancer accounts for 3%
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationClinical/Surgical trials that will change my practice
Clinical/Surgical trials that will change my practice Mr Jim M Adshead Herts and Beds Urological Cancer Centre, Lister Hospital What s changed and where do I feel we are clutching at straws? Regional Specialist
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Final appraisal determination Bevacizumab (first-line), sorafenib (first- and second-line),
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Final appraisal determination Bevacizumab (first-line), sorafenib (first- and secondline), sunitinib (second-line) and temsirolimus (firstline) for
More informationTyrosine Kinase Inhibitors in Clinical Practice: Case Reports
european urology supplements 7 (2008) 610 614 available at www.sciencedirect.com journal homepage: www.europeanurology.com Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports Vincenzo Ficarra
More informationEfficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.5.1971 Efficacy and Toxicity of Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma RESEARCH ARTICLE Efficacy and Toxicity of Sunitinib in Metastatic
More informationTechnology appraisal guidance Published: 25 February 2015 nice.org.uk/guidance/ta333
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment Technology appraisal guidance Published: 25 February 2015 nice.org.uk/guidance/ta333 NICE 2018. All rights
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationCLINICAL INVESTIGATION of new agents and combination
Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma By Robert J. Motzer, Jennifer Bacik, Barbara A. Murphy, Paul Russo, and Madhu Mazumdar
More informationINTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA
INTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA Dr. Michael J. Metcalfe PGY-4 Department of Urologic Sciences University of British Columbia October
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationGUIDELINES FOR THE MANAGEMENT OF
GUIDELINES FOR THE MANAGEMENT OF RENAL CANCER Date of endorsement: July 2011 Authors: Mr. RD Mills & Mr. WH Turner Ref: AngCN-SSG-U3 Page 1 of 14 Approved and Published: Aug 2011 Title: Guidelines for
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationCLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationPrognostic factors in localized renal cell cancer
Original Article PROGNOSTIC FACTORS IN LOCALIZED RENAL CELL CANCER KNIGHT and STADLER Prognostic factors in localized renal cell cancer David A. Knight and Walter M. Stadler Section of Hematology/Oncology,
More informationADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE
Tivozanib Hydrochloride in Advanced Renal Cell Carcinoma ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE AVEO PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139 Tel: (617) 299-5000
More informationPROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY
Journal of IMAB ISSN: 1312-773X http://www.journal-imab-bg.org http://dx.doi.org/10.5272/jimab.2016221.1045 Journal of IMAB - Annual Proceeding (Scientific Papers) 2016, vol. 22, issue 1 PROGNOSTIC FACTORS
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Kidney Cancer. Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2016 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version 2.2016, 11/24/15 National Comprehensive
More informationIntegration of Surgery And Systemic Therapy In The Treatment of
Integration of Surgery And Systemic Therapy In The Treatment of Advanced Renal Cell Carcinoma Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Professorship In Urology
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationAdjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back
Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back Neo adjuvant therapy: Treatment given as a first step to shrink a tumor
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
ipilimumab aligned with patient values. Although few patients had direct experience using this combination agent, patients indicated that side effects associated with nivolumab plus ipilimumab were few
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More information